| Biomarker ID | 549 |
| PMID | 20957673 |
| Year | 2011 |
| Biomarker | Annexin A3 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Urine |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: OR: 0.918 (95% CI: 0.881 – 0.957); Multivariate: OR: 0.899 (95% CI: 0.857 – 0.942) |
| Effect on Pathways | Pathways Include:- Prostaglandin biosynthesis and regulation,Interleukin-5 regulation of apoptosis,Oncostatin M |
| Experiment | Cancer Vs No Malignancy |
| Type of Biomarker | Diagnostic |
| Cohort | 86 untreated patients with CaP and 45 patients with no evidence of malignancy |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.728 (95% CI: 0.635-0.822) |
| Accuracy | NA |
| Level Of Significance | Univariate: p=0.002; Multivariate: p=0.027 |
| Method Used | Western Blot |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | ANXA3 |